Based on the information available, there is currently no specific timeline for the release of a generic version of Teflaro (ceftaroline fosamil). Ceftaroline fosamil is an antibiotic used to treat acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. It is marketed under the brand name Teflaro by the pharmaceutical company Allergan.

According to DrugPatentWatch.com, Teflaro's active ingredient, ceftaroline fosamil, is protected by patents that extend until 2031 [1]. However, it is important to note that the expiration of patents does not necessarily mean that a generic version will immediately become available. The process of obtaining approval from the Food and Drug Administration (FDA) can take several years.

Additionally, DrugPatentWatch.com states that there are no approved generics for Teflaro as of February 2023 [1]. This suggests that, even if there are no patents blocking the development of a generic version, there are currently no approved generics available on the market.

In summary, based on the available information from DrugPatentWatch.com, there is no specific timeline for the release of a generic version of Teflaro. The active ingredient in Teflaro is protected by patents that extend until 2031, and there are currently no approved generics available on the market.

Sources:
[1] DrugPatentWatch.com, "Teflaro (ceftaroline fosamil) Drug Patent Information" (<https://www.drugpatentwatch.com/Drug/Teflaro.html>).